4-iodoquinolin-3-ol | 32435-62-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-iodoquinolin-3-ol
• 英文别名: 4-Iod-3-hydroxy-chinolin
• CAS: 32435-62-4
• 化学式: C₉H₆INO
• 分子量: 271.057
• InChiKey: DLQQTZDRIUELBW-UHFFFAOYSA-N

物化性质

• 熔点：
  172-173 °C
• 沸点：
  319.1±22.0 °C(Predicted)
• 密度：
  1.974±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-iodoquinolin-3-ol 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 N,N-二甲基乙酰胺 、 2-(diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine 、 碳酸氢钠 、 potassium carbonate 、 戴斯-马丁氧化剂 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 44.0h， 生成 C₃₀H₂₂N₄O₂
  参考文献：
  名称：

  用于组装 Atropoenantiomeric 3-Arylindolizines 的有机催化高阶 [8+2] 环加成

  摘要：

  我们在吡啶鎓/异喹啉鎓叶立德和ynals之间提出了前所未有的atroposelective [8+2]环加成反应。值得注意的是，该协议代表了有机催化的 atropoenantioselective 高级环加成反应的一个新例子，以良好的产率和高对映选择性提供各种轴向手性 3-芳基吲哚嗪。此外，获得的轴向手性 3-芳基多嗪也为结构转变和潜在的药物发现提供了许多机会。

  DOI：

  10.1021/acs.orglett.1c03220
• 作为产物：
  描述：

  3-羟基喹啉 在 硫酸 、 双氧水 、 potassium iodide 作用下， 以 甲醇 为溶剂， 反应 9.0h， 生成 4-iodoquinolin-3-ol
  参考文献：
  名称：

  用于组装 Atropoenantiomeric 3-Arylindolizines 的有机催化高阶 [8+2] 环加成

  摘要：

  我们在吡啶鎓/异喹啉鎓叶立德和ynals之间提出了前所未有的atroposelective [8+2]环加成反应。值得注意的是，该协议代表了有机催化的 atropoenantioselective 高级环加成反应的一个新例子，以良好的产率和高对映选择性提供各种轴向手性 3-芳基吲哚嗪。此外，获得的轴向手性 3-芳基多嗪也为结构转变和潜在的药物发现提供了许多机会。

  DOI：

  10.1021/acs.orglett.1c03220

文献信息

• [EN] TOLL-LIKE RECEPTOR 8 AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS TOLL-LIKE 8
  申请人：UNIV KANSAS

  公开号：WO2015095780A1

  公开（公告）日：2015-06-25

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.

  本文描述的化合物可用于治疗目的。这些化合物可以是TLR激动剂，例如TLR8激动剂。这些化合物可以包含在药物组合物中，并用于治疗需要TLR8激动剂的情况。药物组合物可以包括任何成分，例如载体、稀释剂、赋形剂、填料或其他在药物组合物中常见的成分。这些化合物可以是本文所述的化合物，以及其衍生物、前药、盐、立体异构体，或在任何手性中心具有任何手性，或互变异构体、多晶形态、溶剂合剂，或其组合。因此，这些化合物可以用作疫苗的辅助剂，以及用于本文描述的其他治疗目的。这些化合物可以具有本文描述的任何一个化学式或其衍生物。
• Rhodium‐Catalyzed Atroposelective Click Cycloaddition of Azides and Alkynes
  作者：Linwei Zeng、Jiaming Li、Sunliang Cui

  DOI：10.1002/anie.202205037

  日期：2022.7.11

  A rhodium-catalyzed enantioselective click cycloaddition of azides and alkynes for rapid and modular access to atropisomeric triazoles is reported. This click process features very mild reaction conditions, superior efficiency and enantioselectivity, broad substrate scope and facile scalability. The racemization study and further derivatizations demonstrate the good configurational stability of the

  报道了一种铑催化的叠氮化物和炔烃的对映选择性点击环加成，用于快速和模块化地获得阻转异构三唑。这种点击过程具有非常温和的反应条件、卓越的效率和对映选择性、广泛的底物范围和易于扩展的特点。外消旋研究和进一步的衍生化证明了所获得的轴向手性三唑产物具有良好的构型稳定性。
• Toll-like receptor 8 agonists
  申请人：The University Of Kansas

  公开号：US10654807B2

  公开（公告）日：2020-05-19

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.

  本文所述化合物可用于治疗目的。这些化合物可以是 TLR 激动剂，如 TLR8 激动剂。这些化合物可以包含在药物组合物中，用于治疗TLR8激动剂有用的疾病。药物组合物可以包括任何成分，例如药物组合物中常见的载体、稀释剂、赋形剂、填料或类似物。化合物可以是本文图示或描述的化合物，也可以是其衍生物、原药、盐或立体异构体，或在任何手性中心具有任何手性的化合物，或同系物、多晶型物、溶胶或其组合。因此，这些化合物可用作疫苗佐剂，也可用于本文所述的其他治疗目的。这些化合物可以具有本文所述的任何一种式子或其衍生物。
• Exquisite Selectivity for Human Toll-Like Receptor 8 in Substituted Furo[2,3-<i>c</i>]quinolines
  作者：Hari Prasad Kokatla、Diptesh Sil、Subbalakshmi S. Malladi、Rajalakshmi Balakrishna、Alec R. Hermanson、Lauren M. Fox、Xinkun Wang、Anshuman Dixit、Sunil A. David

  DOI：10.1021/jm400694d

  日期：2013.9.12

  Toll-like receptor (TLR)-8 agonists activate adaptive immune responses by inducing robust production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds may be promising candidate adjuvants. We synthesized and evaluated hitherto unexplored furo[2,3-d]quinolines and regioisomeric furo[3,2-c]quinolines derived via a tandem, one-pot Sonogashira coupling and intramolecular 5-endo-dig cyclization strategy in a panel of primary screens. We observed a pure TLR8-agonistic activity profile in select furo[2,3-c]quinolines, with maximal potency conferred by a C2-butyl group (EC50 = 1.6 mu M); shorter, longer, or substituted homologues as well as compounds bearing C1 substitutions were inactive, which was rationalized by docking studies using the recently described crystal structure of human TLR8. The best-in-class compound displayed,prominent proinflammatory cytokine induction (including interleukin-12 and interleukin-18), but was bereft of interferon-alpha inducing properties, confirming its high selectivity for human TLR8.
• Toll-Like Receptor 8 Agonists
  申请人：David Sunil Abraham

  公开号：US20160347715A1

  公开（公告）日：2016-12-01

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.